PNC Financial Services Group Inc. Purchases 2,916 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

PNC Financial Services Group Inc. lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 25.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,278 shares of the medical research company’s stock after acquiring an additional 2,916 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Charles River Laboratories International were worth $2,636,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Edgestream Partners L.P. bought a new stake in Charles River Laboratories International during the 4th quarter worth about $2,378,000. E Fund Management Co. Ltd. acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth approximately $336,000. Raymond James Financial Inc. bought a new stake in shares of Charles River Laboratories International during the fourth quarter worth approximately $42,776,000. Arizona State Retirement System lifted its holdings in Charles River Laboratories International by 1.6% in the fourth quarter. Arizona State Retirement System now owns 14,995 shares of the medical research company’s stock valued at $2,768,000 after buying an additional 237 shares during the period. Finally, Proficio Capital Partners LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at approximately $10,768,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 2.6 %

NYSE:CRL opened at $171.27 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock’s 50 day moving average price is $167.74 and its two-hundred day moving average price is $184.72. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $274.77. The firm has a market capitalization of $8.76 billion, a price-to-earnings ratio of 1,141.78, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period in the previous year, the business earned $2.46 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of analyst reports. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. The Goldman Sachs Group decreased their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Robert W. Baird cut their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. Finally, Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $198.36.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).